68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer: diagnostic sensitivity and interobserver agreement
- 112 Downloads
To determine the diagnostic sensitivity and interobserver agreement of Gallium 68-prostate-specific membrane antigen positron emission tomography/computed tomography (68Ga-PSMA-11 PET/CT) imaging for diagnosis and staging of patients with newly diagnosed prostate cancer (PC).
Materials and methods
One hundred and seventy-three men (mean age, 68 ± 7.7 years; range 46–84 years) with newly diagnosed, untreated PC were enrolled in this prospective study between January 2017 and August 2018. All patients underwent a 68Ga-PSMA-11 PET/CT examination. For each patient, we determined the disease stage, the Gleason score, and the maximum standardized uptake value (SUVmax) for primary prostatic tumor and extraprostatic metastases. The diagnostic sensitivity and interobserver agreement of 68Ga-PSMA-11 PET/CT for diagnosis and staging of PC were established by histopathology as the reference standard.
68Ga-PSMA-11 PET/CT examinations were interpreted as positive for PC in 166 of 173 patients (101 patients had primary prostatic tumor only, two patients had extraprostatic metastases only and 63 patients had combined lesions). The sensitivity of 68Ga-PSMA-11 PET/CT examination in the diagnosis of PC was 96%. 68Ga-PSMA-11 PET/CT produced a significant change of stage in 28.6% patients with an upstage in 17.9% patients and a downstage in 10.7% patients. The interobserver agreements were almost good to perfect (k = 0.63–0.89) for visual image interpretation, SUVmax measurement, and tumor staging.
68Ga-PSMA-11 PET/CT is a valuable tool with high diagnostic sensitivity (96%) and high reproducibility for diagnosis and staging of patients with newly diagnosed PC.
Keywords68Ga-PSMA-11 PET/CT Newly diagnosed Prostate cancer Interobserver agreement
The authors thank all staff members and colleagues in the PET CT Unite - MISR RADIOLOGY center (MRC)-Egypt for their helpful cooperation and all the study participants for their patience and support.
The authors state that this work has not received any funding.
Compliance with ethical standards
Conflict of interest
The authors of this manuscript declare no relevant conflicts of interest, and no relationships with any companies, whose products or services may be related to the subject matter of the article.
Institutional review board approval was obtained.
Written informed consent was obtained from all patients.
- 1.Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011; 61: 69–90.Google Scholar
- 4.Kosuri S, Akhtar NH, Smith M, et al. Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy. Adv Urol 2012; 2012.Google Scholar
- 6.Heidenreich A, Bastian PJ, Bellmunt J, et al. European Association of Urology. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65:467–479.Google Scholar
- 7.Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur urol 2017; 71:618–629.Google Scholar
- 10.Budiharto T, Joniau S, Lerut E, et al. Prospective evaluation of C-11-choline positron emission tomography/computed tomography and diffusion weighted magnetic resonance imaging for the nodal staging of prostate cancer with high risk lymph node metastases. Eur Urol 2011; 60:125–130.CrossRefGoogle Scholar
- 12.Lopci E, Chiti A, Lazzeri M. Re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for 18F/11C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur Urol 2016; 70: e112–e113.Google Scholar
- 14.Buyyounouski MK, Choyke PL, McKenney JK, et al. Prostate cancer–major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: a cancer journal for clinicians 2017; 67:245-53.Google Scholar
- 16.Kallur KG, Ramachandra PG, Rajkumar K, et al. Clinical utility of gallium-68 PSMA PET/CT scan for prostate cancer. Indian journal of nuclear medicine: IJNM: the official journal of the Society of Nuclear Medicine, India 2017; 32:110–117.Google Scholar
- 22.Berger I, Annabattula C, Lewis J, et al. 68 Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology. Prostate cancer and prostatic diseases 2018; 21:204–211.Google Scholar
- 28.Schreiter V, Gericke M, Beck M, Ghadjar P, Boening G, Schreiter NF. Usefulness of Ga-68 HBED-CC PSMA PET/CT for Tumor Staging in the Initial Diagnostic Assessment of Prostate Cancer. J Nucl Med Radiat Ther 2016; 7: 291.Google Scholar